Castle Creek Biosciences, Inc.

2:00 PM - 2:15 PM (PDT), Wednesday, June 15, 2022

Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, is using two lentiviral vector delivery platforms to develop and commercialize gene therapies that initially target skin, connective tissue and metabolic diseases. Our scientists use in vivo and ex vivo technologies to switch gene targets and create optimal therapies for a multitude of genetic diseases. Castle Creek Biosciences is a portfolio company of Paragon Biosciences, LLC.

Company Type:
Privately Funded Company
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
D-Fi gene therapy for treatment of recessive dystrophic epidermolysis bullosa (RDEB)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
PRESIDENT AND CEO
Castle Creek Biosciences